694 related articles for article (PubMed ID: 31231370)
1. Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation.
Pende D; Falco M; Vitale M; Cantoni C; Vitale C; Munari E; Bertaina A; Moretta F; Del Zotto G; Pietra G; Mingari MC; Locatelli F; Moretta L
Front Immunol; 2019; 10():1179. PubMed ID: 31231370
[TBL] [Abstract][Full Text] [Related]
2. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications.
Sivori S; Vacca P; Del Zotto G; Munari E; Mingari MC; Moretta L
Cell Mol Immunol; 2019 May; 16(5):430-441. PubMed ID: 30778167
[TBL] [Abstract][Full Text] [Related]
3. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation.
Moretta L; Locatelli F; Pende D; Marcenaro E; Mingari MC; Moretta A
Blood; 2011 Jan; 117(3):764-71. PubMed ID: 20889923
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cells: From surface receptors to the cure of high-risk leukemia (Ceppellini Lecture).
Falco M; Pende D; Munari E; Vacca P; Mingari MC; Moretta L
HLA; 2019 Apr; 93(4):185-194. PubMed ID: 30828978
[TBL] [Abstract][Full Text] [Related]
5. Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.
Zhao XY; Yu XX; Xu ZL; Cao XH; Huo MR; Zhao XS; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
Blood Adv; 2019 Dec; 3(24):4312-4325. PubMed ID: 31869417
[TBL] [Abstract][Full Text] [Related]
6. Markers and function of human NK cells in normal and pathological conditions.
Del Zotto G; Marcenaro E; Vacca P; Sivori S; Pende D; Della Chiesa M; Moretta F; Ingegnere T; Mingari MC; Moretta A; Moretta L
Cytometry B Clin Cytom; 2017 Mar; 92(2):100-114. PubMed ID: 28054442
[TBL] [Abstract][Full Text] [Related]
7. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.
Pende D; Marcenaro S; Falco M; Martini S; Bernardo ME; Montagna D; Romeo E; Cognet C; Martinetti M; Maccario R; Mingari MC; Vivier E; Moretta L; Locatelli F; Moretta A
Blood; 2009 Mar; 113(13):3119-29. PubMed ID: 18945967
[TBL] [Abstract][Full Text] [Related]
8. Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality.
Mancusi A; Ruggeri L; Urbani E; Pierini A; Massei MS; Carotti A; Terenzi A; Falzetti F; Tosti A; Topini F; Bozza S; Romani L; Tognellini R; Stern M; Aversa F; Martelli MF; Velardi A
Blood; 2015 May; 125(20):3173-82. PubMed ID: 25769621
[TBL] [Abstract][Full Text] [Related]
9. NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation.
Björklund AT; Schaffer M; Fauriat C; Ringdén O; Remberger M; Hammarstedt C; Barrett AJ; Ljungman P; Ljunggren HG; Malmberg KJ
Blood; 2010 Apr; 115(13):2686-94. PubMed ID: 20097883
[TBL] [Abstract][Full Text] [Related]
10. Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias.
Moretta A; Locatelli F; Moretta L
Immunol Rev; 2008 Aug; 224():58-69. PubMed ID: 18759920
[TBL] [Abstract][Full Text] [Related]
11. Human NK cells: From surface receptors to clinical applications.
Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the natural killer cell KIR repertoire by cytomegalovirus infection.
Charoudeh HN; Terszowski G; Czaja K; Gonzalez A; Schmitter K; Stern M
Eur J Immunol; 2013 Feb; 43(2):480-7. PubMed ID: 23161492
[TBL] [Abstract][Full Text] [Related]
13. Expansion of NKG2A-LIR1- natural killer cells in HLA-matched, killer cell immunoglobulin-like receptors/HLA-ligand mismatched patients following hematopoietic cell transplantation.
Rathmann S; Glatzel S; Schönberg K; Uhrberg M; Follo M; Schulz-Huotari C; Kaymer M; Veelken H; Finke J; Fisch P
Biol Blood Marrow Transplant; 2010 Apr; 16(4):469-81. PubMed ID: 20044012
[TBL] [Abstract][Full Text] [Related]
14. Recipient expression of ligands for donor inhibitory KIRs enhances NK-cell function to control leukemic relapse after haploidentical transplantation.
Zhao XY; Chang YJ; Zhao XS; Xu LP; Zhang XH; Liu KY; Li D; Huang XJ
Eur J Immunol; 2015 Aug; 45(8):2396-408. PubMed ID: 25952732
[TBL] [Abstract][Full Text] [Related]
15. Partial break in tolerance of NKG2A
Rathmann S; Keck C; Kreutz C; Weit N; Müller M; Timmer J; Glatzel S; Follo M; Malkovsky M; Werner M; Handgretinger R; Finke J; Fisch P
Bone Marrow Transplant; 2017 Aug; 52(8):1144-1155. PubMed ID: 28481352
[TBL] [Abstract][Full Text] [Related]
16. Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high-risk leukaemias.
Moretta A; Pende D; Locatelli F; Moretta L
Clin Exp Immunol; 2009 Sep; 157(3):325-31. PubMed ID: 19664139
[TBL] [Abstract][Full Text] [Related]
17. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
[TBL] [Abstract][Full Text] [Related]
18. How important is NK alloreactivity and KIR in allogeneic transplantation?
Shaffer BC; Hsu KC
Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
[TBL] [Abstract][Full Text] [Related]
19. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands.
Yu J; Heller G; Chewning J; Kim S; Yokoyama WM; Hsu KC
J Immunol; 2007 Nov; 179(9):5977-89. PubMed ID: 17947671
[TBL] [Abstract][Full Text] [Related]
20. Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.
Cooley S; Parham P; Miller JS
Blood; 2018 Mar; 131(10):1053-1062. PubMed ID: 29358179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
